As with the STAT3 inhibitors, the JAK inhibitor blocked both the macrophage STAT3 activation and pathological macrophage differentiation induced during ADPKD-CM-mediated programming (Fig. 5G-H). This evidence concerns the gene STAT3 and autosomal dominant polycystic kidney disease.